trending Market Intelligence /marketintelligence/en/news-insights/trending/cYe5mn0mpeD43_IbrvAyEQ2 content esgSubNav
In This List

German Merck plans to seek US FDA approval for multiple sclerosis drug

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022

Blog

Insight Weekly: Reviving nuclear power; 2023 outlook for US financials; PE funds fuel EV sector


German Merck plans to seek US FDA approval for multiple sclerosis drug

Merck KGaA plans to seek the U.S. Food and Drug Administration's approval for its multiple sclerosis treatment Mavenclad in the second quarter of 2018, Reuters reported Dec. 14, citing Belen Garijo, the head of the healthcare division.

The company had previously filed for approval in 2011, but the FDA's concerns caused the company to end its development plans for the drug. The company later resumed its plans for the drug, focusing on patients with highly active relapsing multiple sclerosis, and received approval in Europe in August.

Garijo told Reuters that unlike Roche Holding AG's Ocrevus, which is an infusion drug, Mavenclad was not developed for treating primary progressive multiple sclerosis.